New 48-week data from the Phase IIIb APEX trial (NCT04882098) show Tremfya (guselkumab; Johnson & Johnson) produces sustained inhibition of radiographic progression and improved clinical symptoms in ...

This therapy is good for people with chronic pain, people with fibromyalgia, arthritis, any kind of inflammation,” said owner ...

FibroBiologics is conducting a prospective, multicenter, randomized clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to ...